Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Quantum Private Wealth LLC

Quantum Private Wealth LLC trimmed its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 22.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 30,142 shares of the biopharmaceutical company’s stock after selling 8,519 shares during the period. Intra-Cellular Therapies accounts for approximately 0.8% of Quantum Private Wealth LLC’s holdings, making the stock its 24th largest holding. Quantum Private Wealth LLC’s holdings in Intra-Cellular Therapies were worth $2,517,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Intra-Cellular Therapies by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock worth $1,878,000 after acquiring an additional 2,157 shares during the last quarter. Barclays PLC boosted its holdings in shares of Intra-Cellular Therapies by 282.0% in the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock valued at $2,521,000 after purchasing an additional 25,435 shares during the last quarter. Oak Ridge Investments LLC grew its stake in shares of Intra-Cellular Therapies by 74.1% during the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock valued at $1,656,000 after buying an additional 8,440 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Intra-Cellular Therapies by 31.9% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company’s stock worth $33,258,000 after buying an additional 109,892 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of Intra-Cellular Therapies by 3.3% in the 3rd quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company’s stock worth $43,735,000 after buying an additional 18,865 shares during the period. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. StockNews.com started coverage on Intra-Cellular Therapies in a report on Sunday. They issued a “hold” rating on the stock. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their price target for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Needham & Company LLC restated a “hold” rating and set a $100.00 target price on shares of Intra-Cellular Therapies in a report on Monday, January 13th. Finally, JPMorgan Chase & Co. increased their price target on Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a report on Monday, November 4th. Nine investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Intra-Cellular Therapies presently has a consensus rating of “Moderate Buy” and an average target price of $103.62.

Intra-Cellular Therapies Stock Performance

NASDAQ:ITCI opened at $127.82 on Friday. The stock has a market cap of $13.59 billion, a price-to-earnings ratio of -146.92 and a beta of 0.72. Intra-Cellular Therapies, Inc. has a one year low of $62.78 and a one year high of $128.19. The business’s 50-day simple moving average is $105.80 and its 200 day simple moving average is $87.97.

Insiders Place Their Bets

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. This represents a 4.55 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 2.60% of the stock is owned by company insiders.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.